Publications by authors named "Alexander Sherry"

Claim this Profile
T
The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer.
Alexander D Sherry, Krishan R Jethwa, Pavlos Msaouel, Ethan B Ludmir

Lancet Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Noncomparative Comparisons: The Paradox of Randomized Noncomparative Trials.
Alexander D Sherry, Ethan B Ludmir, Pavlos Msaouel

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential censoring in overall survival in phase 3 oncology clinical trials.
Eric J Hsu, Alexander D Sherry, Timothy A Lin, Joseph Abi Jaoude, Ramez Kouzy

J Natl Cancer Inst· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial.
Alexander D Sherry, Bilal A Siddiqui, Cara Haymaker, Bryan M Fellman, Marina N Medina-Rosales

Eur Urol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bayesian interim analysis and efficiency of phase III randomized trials.
Alexander D Sherry, Pavlos Msaouel, Avital M Miller, Timothy A Lin, Gabrielle S Kupferman

Br J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial.
Chad Tang, Alexander D Sherry, Aaron Seo, Kieko Hara, Haesun Choi

Lancet Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contemporary Advances, Evidence, and Considerations in Preoperative Therapy for Pancreatic Ductal Adenocarcinoma.
Alexander D Sherry, Alexandra K Bennett, Ryan M Carr, Mark J Truty, Krishan R Jethwa

Semin Radiat Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rethinking End Points in Modern Oncology Trials-Beyond the P Value-Reply.
Alexander D Sherry, Pavlos Msaouel, Ethan B Ludmir

JAMA Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Random Assignment, But Without Comparison: A Missed Opportunity.
Alexander D Sherry, Ethan B Ludmir, Pavlos Msaouel

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect size estimation in cooperative group- and industry-sponsored phase 3 oncology trials.
Sonal S Noticewala, Adam J Grippin, Ramez Kouzy, Joseph Abi Jaoude, Avital Miller, Alexander Sherry

J Natl Cancer Inst· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reproducibility of statistically significant phase III oncology trials: An In Silico meta-epidemiological analysis.
Alexander D Sherry, Pavlos Msaouel, Avital M Miller, Timothy A Lin, Joseph Abi Jaoude

Eur J Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial.
Alexander D Sherry, Stephanie O Dudzinski, Ethan B Ludmir

Lancet· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient, Physician, and Assessor Blinding in Phase III Randomized Trials in Oncology: A Meta-Epidemiological Analysis.
Gabrielle Brown, Pavlos Msaouel, Avital M Miller, Ramez Kouzy, Timothy A Lin, Alexander D Sherry

Cancer Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incomplete Toxicity Reporting and Use of Toxicity-Minimizing Language in Phase III Oncology Trials.
Avital M Miller, Adina H Passy, Alexander D Sherry, Ramez Kouzy, Joseph Abi Jaoude

JCO Oncol Pract· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials: A Meta-Epidemiological Analysis.
Alexander D Sherry, Avital M Miller, Jnana Preeti Parlapalli, Gabrielle S Kupferman, Esther J Beck

JAMA Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival-inferred fragility of statistical significance in phase III oncology trials.
Alexander D Sherry, Yufei Liu, Pavlos Msaouel, Timothy A Lin, Alex Koong

NPJ Precis Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body composition as a potential biomarker of recurrence risk in patients with triple-negative breast cancer.
Jill B De Vis, Cong Wang, Kirsten V Nguyen, Lili Sun, Brigitte Jia, Alexander D Sherry

Breast Cancer Res Treat· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Local Control and Extended Survival in Locally Advanced Hepatocellular Carcinoma.
Alexander D Sherry, Ahmed O Kaseb, Ethan B Ludmir

JAMA Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial.
Jarey H Wang, Alexander D Sherry, Soha Bazyar, Philip Sutera, Noura Radwan

J Clin Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Misunderstood trial design: randomisation compels comparison.
Alexander D Sherry, Bora Lim, Ethan B Ludmir, Pavlos Msaouel

Lancet Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment group-specific inferences in Phase III Randomized Oncology Trials.
Alexander D Sherry, Adina H Passy, Joseph Abi Jaoude, Timothy A Lin, Ramez Kouzy

Acta Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sunitinib for the treatment of phaeochromocytomas and paragangliomas.
Alexander D Sherry, Ethan B Ludmir, Pavlos Msaouel

Lancet· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolving Paradigms in the Treatment of Oligometastatic Pancreatic Ductal Adenocarcinoma.
Enoch Chang, Alexander D Sherry, Jakob Liermann, Amir Abdollahi, Ching-Wei D Tzeng

J Gastrointest Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival-Inferred Fragility of Statistical Significance in Phase III Oncology Trials.
Alexander D Sherry, Yufei Liu, Pavlos Msaouel, Timothy A Lin, Alex Koong

medRxiv· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trials.
Alexander D Sherry, Pavlos Msaouel, Timothy A Lin, Joseph Abi Jaoude, Ramez Kouzy

BMJ Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis